Related Experiment Video
Updated: Jan 22, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Endovascular treatment of surgical mesoportal and portosystemic shunt dysfunction in pediatric patients
Elliot J Stein1, Giridhar M Shivaram1, Kevin S H Koo1
1Department of Radiology, Section of Interventional Radiology, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S R-5417, Seattle, WA, 98105, USA.
Insights
Interventional radiology effectively treats dysfunctional pediatric surgical shunts, maintaining patency through endovascular procedures. Reintervention is often necessary, but assisted patency rates remain high for these mesoportal and portosystemic shunts.
Area of Science:
- Vascular Surgery
- Pediatric Interventional Radiology
- Hepatobiliary Surgery
Background:
- Limited published data exists on endovascular treatment of dysfunctional mesoportal and portosystemic shunts in pediatric patients.
- Surgical shunts are created to manage conditions like portal hypertension, but can become dysfunctional over time.
Purpose of the Study:
- To describe the treatment and follow-up of dysfunctional pediatric mesoportal and portosystemic shunts managed by interventional radiology.
- To test the hypothesis that stenotic and occluded shunts can be maintained patent using interventional radiology techniques in the short to medium term.
Main Methods:
- A single-center retrospective study included pediatric patients with surgical mesoportal (Meso-Rex) or portosystemic shunts treated between 2010 and 2018.
- Interventions included angioplasty and stenting, with technical success defined by venographic evidence of improved flow.
- Primary outcomes were shunt patency at 1, 6, 12, and 24 months, and freedom from reintervention.
Main Results:
- Twenty pediatric patients underwent 52 interventions on various types of shunts due to failure.
- Technical success was 100% for stenotic shunts and 66.7% for occluded shunts.
- Primary patency rates at 24 months were 40%, but 100% of shunts were either primarily or primarily-assisted patent with reintervention. Median freedom from reintervention was 387 days.
Conclusions:
- Endovascular methods provide effective management for dysfunctional surgical portosystemic shunts in pediatric patients.
- While reinterventions are frequently required, excellent combined primary and assisted primary patency rates are achievable.
Background:
Published data describing the endovascular treatment of dysfunctional mesoportal and portosystemic shunts in the pediatric population are limited.
Objective:
We sought to describe the treatment and follow-up of such shunts managed by interventional radiology at a single pediatric hospital. We hypothesized that stenotic and occluded pediatric portosystemic and mesoportal shunts can be maintained patent by interventional radiology in the moderate term.
Materials And Methods:
We conducted a single-center retrospective study at a tertiary pediatric hospital. We included children with surgical mesoportal (meso-Rex) or portosystemic (mesocaval, splenorenal or splenocaval) shunts treated with attempted angioplasty or stenting from 2010 to 2018. Technical success was defined as catheterization and intervention upon the shunt with venographic evidence of flow improvement. The primary outcome variables were shunt patency at 1 month, 6 months, 12 months and 24 months post-procedure and freedom from reintervention.
Results:
Twenty pediatric patients (11 boys, 9 girls; mean age 8.25 years, range 1.3-17 years) met inclusion criteria. Fifty-two interventions (primary and reintervention) on 13 splenorenal, 3 meso-Rex, 2 mesocaval and 2 splenocaval shunts were performed because of evidence of shunt failure, including gastrointestinal bleeding, hypersplenism, or radiographic evidence of a flow defect. The 11 stenotic shunts were treated with 100% technical success, while the remaining 9 occluded shunts were treated with 66.7% technical success. The mean number of reinterventions was 1.9 (standard deviation [SD] = 3.1) per child, which did not differ between stenotic and occluded shunts (P=0.24). Primary patency at 1-month, 6-month, 12-month and 24-months follow-up visits was 17/17 (100%), 10/16 (62.5%), 7/15 (46.7%) and 4/10 (40%), respectively. However, 100% of shunts were either primary patent or primary-assisted patent by endovascular reintervention. There were no cases of shunt occlusion following initial technical success. Finally, the median freedom from reintervention duration was 387 days (SD=821 days).
Conclusion:
Dysfunctional portosystemic surgical shunts are effectively managed by endovascular methods. While many shunts require reintervention, combined primary patency and assisted primary patency rates are excellent.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Shunt Admittances
To model this effect, the method of images is employed. This method involves replacing the Earth with an image conductor that mirrors the original...
Kidney Transplant II: Surgical Procedure

